Drug delivery by aerosol may have several advantages over other modes, particularly if the lung is the target organ. Aerosol delivery may allow achievement of higher concentrations while minimizing systemic effects and offers convenience, rapid onset of action, and avoidance of the needles and sterile technique necessary with intravenous drug administration. Aerosol delivery may change the pharmacokinetics of many drugs, however, and an awareness of the caveats of aerosolized drug delivery is mandatory to ensure both safety and adequate drug delivery. This paper discusses the administration of surfactants, anti-inflammatory agents, and analgesics by the aerosol route.
HessD. Nebulizers: principles and performance. Respir Care, 2000; 45(6):609-622.
2.
MinocchieriS, BurrenJM, BachmannMA, SternG, WildhaberJ, BuobS, et al. Development of the premature infant nose throat-model (PrINT model): an upper airway replica of a premature neonate for the study of aerosol delivery. Pediatr Res, 2008; 64(2):141-146.
3.
DolovichM. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir Care, 2000; 45(11):597-608.
4.
JobeAH. Pulmonary surfactant therapy. N Engl J Med, 1993; 328(12):861-868.
5.
WareLB, MatthayMA. The acute respiratory distress syndrome. N Engl J Med, 2000; 342(18):1334-1349.
YostC, SollR. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev, 2002;(2):CD001456.
8.
JobeAH, BancalariE. Bronchopulmonary dysplasia. Am J Respir Crit Care Med, 2001; 163(7):1723-1729.
9.
RobillardE, AlarieY, Dagenais-PerusseP, BarilE, GuilbeaultA. Microaerosol administration of synthetic β,γ-dipalmitoyl-L-α-lecithin in the respiratory distress syndrome: a preliminary report. Can Med Assoc J, 1964; 90(2):55-57.
10.
ChuJ, ClementsJA, CottonEK, KlausMH, SweetAY, TooleyWH. Neonatal pulmonary ischemia. I. Clinical and physiologic studies. Pediatrics, 1967; 40(4):Suppl:709-782.
11.
AnzuetoA, BaughmanRP, GuntupalliKK, WegJG, WiedemannHP, RaventósAA, LemaireF, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med, 1996; 334(22):1417-1421.
12.
EnhörningG, GrossmanG, RobertsonB. Tracheal deposition of surfactant before the first breathe. Am Rev Respir Dis, 1973; 107(6):921-927.
MorleyCJ, MillerN, BanghamAD, DavisJA. Dry artificial lung surfactant and its effect on very premature babies. Lancet, 1981; 317(8211):64-68.
15.
PillowJJ, MinocchieriS. Innovation in surfactant therapy. II. Surfactant administration by aerosolization. Neonatology, 2012; 101(4):337-344.
16.
SunY, YangR, ZhongJG, FangF, JiangJJ, LiuM, LuJ. Aerosolized surfactant generated by a novel noninvasive apparatus reduced lung injury in rats. Crit Care, 2009; 13(2):R31.
17.
RubinBK. Pediatric aerosol therapy: new devices and new drugs. Respir Care, 2011; 56(9):1411-1421; discussion 1421-1423.
18.
LewisJF, TaborB, IkegamiM, JobeAH, JosephM, AbsolomD. Lung function and surfactant distribution in saline-lavaged sheep given instilled vs nebulized surfactant. J Appl Physiol, 1993; 74(3):1256-1264.
19.
LewisJF, GoffinJ, YueP, McCaigLA, BjarnesonD, VeldhuizenRA. Evaluation of exogenous surfactant treatment strategies in an adult model of acute lung injury. J Appl Physiol, 1996; 80(4):1156-1164.
20.
FokTF, al-EssaM, DolovichM, RasidF, KirpalaniH. Nebulization of surfactants in an animal model of neonatal respiratory distress. Arch Dis Child Fetal Neonatal Ed, 1998; 78(1):F3–F9.
21.
LamplandAL, WolfsonMR, MazelaJ, HendersonC, GregoryTJ, MeyersP, et al. Aerosolized KL4 surfactant improves short-term survival and gas exchange in spontaneously breathing newborn pigs with hydrochloric acid-induced acute lung injury. Pediatr Pulmonol, 2014; 49(5):482-489.
22.
RuppertC, KuchenbuchT, BoenschM, SchmidtS, MathesU, HillebrandV, et al. Dry powder aerosolization of a recombinant surfactant protein C-based surfactant for inhalative treatment of the acutely inflamed lung. Crit Care Med, 2010; 38(7):1584-1591.
23.
DijkPH, HeikampA, Bambang OetomoS. Surfactant nebulization prevents the adverse effects of surfactant therapy on blood pressure and cerebral blood flow in rabbits with severe respiratory failure. Intensive Care Med, 1997; 23(10):1077-1081.
24.
SchermulyRT, GüntherA, WeissmannN, GhofraniHA, SeegerW, GrimmingerF, WalmrathD. Differential impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (V̇A/Q̇) mismatch in a model of acute lung injury. Am J Respir Crit Care Med, 2000; 161(1):152-159.
25.
Rey-SantanoC, MielgoVE, AndresL, Ruiz-del-YerroE, Valls-i-SolerA, MurgiaX. Acute and sustained effects of aerosolized vs. bolus surfactant therapy in premature lambs with respiratory distress syndrome. Pediatr Res, 2013; 73(5):639-646.
26.
WagnerMH, AmthauerH, SonntagJ, DrenkF, EichstädtHW, ObladenM. Endotracheal surfactant atomization: an alternative to bolus instillation?. Crit Care Med, 2000; 28(7):2540-2544.
27.
JorchG, HartlH, RothB, KribsA, GortnerL, SchaibleT, et al. Surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants. Pediatr Pulmonol, 1997; 24(3):222-224.
28.
ArroeM, Pedersen-BjergaardL, AlbertsenP, BodeS, GreisenG, JonsboF, et al. Inhalation of aerosolized surfactant (Exosurf) to neonates treated with nasal continuous positive airway pressure. Prenat Neonat Med, 1998; 3(3):346-352.
29.
BerggrenE, LiljedahlM, WinbladhB, AndreassonB, CurstedtT, RobertsonB, SchollinJ. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr, 2000; 89(4):460-464.
30.
FinerNN, MerrittTA, BernsteinG, JobL, MazelaJ, SegalR. An open label, pilot study of Aerosurf combined with nCPAP to prevent RDS in preterm neonates. J Aerosol Med Pulm Drug Deliv, 2010; 23(5):303-309.
31.
WillsonDF, EganEE, NotterR. Exogenous surfactant in the pediatric patient. In: RimensbergerPC. Neonatal and pediatric mechanical ventilation: from basics to clinical practice. Berlin: Springer-Verlag; 2014.
32.
AnzuetoA, JubranA, OharJA, PiquetteCA, RennardSI, ColiceG, et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis. JAMA, 1997; 278(17):1426-1431.
33.
CorcoranTE, ThomasKM, GaroffS, TiltonRD, PrzybycienTM, PilewskiJM. Imaging the postdeposition dispersion of an inhaled surfactant aerosol. J Aerosol Med Pulm Drug Deliv, 2012; 25(5):290-296.
34.
GrieseM, BuflerP, TellerJ, ReinhardtD. Nebulization of a bovine surfactant in cystic fibrosis: a pilot study. Eur Respir J, 1997; 10(9):1989-1994.
35.
StrüberM, CremerJ, HarringerW, HirtSW, Costard-JäckleA, HaverichA. Nebulized synthetic surfactant in reperfusion injury after single lung transplantation. J Thorac Cardiovasc Surg, 1995; 110(2):563-564.
36.
BabuKS, WoodcockDA, SmithSE, StaniforthJN, HolgateST, ConwayJH. Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma. Eur Respir J, 2003; 21(6):1046-1049.
37.
KurashimaK, OgawaH, OhkaT, FujimuraM, MatsudaT, KobayashiT. A pilot study of surfactant inhalation in the treatment of asthma attack. Arerugi, 1991; 40(2):160-163.
38.
OetomoSB, DorrepaalC, BosH, GerritsenJ, van der MarkTW, KoëterGH, van AalderenWM. Surfactant nebulization does not alter airflow obstruction and bronchial responsiveness to histamine in asthmatic children. Am J Respir Crit Care Med, 1996; 153(3):1148-1152.
39.
WinklerC, HohlfeldJM. Surfactant and allergic airway inflammation. Swiss Med Wkly, 2013; 143:w13818.
40.
WillsonDF, ThomasNJ, TamburroR, TruemperE, TruwitJ, ConawayM, et al. Pediatric calfactant in acute respiratory distress syndrome trial. Pediatr Crit Care Med, 2013; 14(7):657-665.
41.
de BenedictisFM, BushA. Corticosteroids in respiratory diseases in children. Am J Respir Crit Care Med, 2012; 185(1):12-23.
42.
YehTF, LinYJ, LinHC, HuangCC, HsiehWS, LinCH, TsaiCH. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med, 2004; 350(13):1304-1313.
43.
CheongJL, BurnettAC, LeeKJ, RobertsG, ThompsonDK, WoodSJ, et al. Association between postnatal dexamethasone for treatment of bronchopulmonary dysplasia and brain volumes at adolescence in infants born prematurely. J Pediatr, 2014; 164(4):737.e1-743.e1.
44.
LaiHC, FitzSimmonsSC, AllenDB, KosorokMR, RosensteinBJ, CampbellPW, FarrellPM. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med, 2000; 342(12):851-859.
45.
AbrougF, Ouanes-BesbesL, Fkih-HassenM, OuanesI, AyedS, DachraouiF, et al. Prednisone in COPD exacerbation requiring ventilator support: an open-label randomized evaluation. Eur Respir J, 2014; 43(3):717-724.
46.
LeuppiJD, SchuetzP, BingisserR, BodmerM, BrielM, DrescherT, et al. Short-term vs. conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA, 2013; 309(21):2223-2231.
47.
BarnesPJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol, 1998; 102(4):531-538.
48.
PauwelsRA, PedersenS, BusseWW, TanWC, ChenYZ, OhlssonSV, et al. Early intervention with budesonide in mild persistent asthma: a randomized, double-blind trial. Lancet, 2003; 361(9363):1071-1076.
49.
SuissaS, ErnstP, BenayounS, BaltzanM, CaiB. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med, 2000; 343(5):332-336.
50.
KellyHW, SternbergAL, LescherR, FuhlbriggeAL, WilliamsP, ZeigerRS, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med, 2012; 367(10):904-912.
51.
BousheyHA, SorknessCA, KingTS, SullivanSD, FahyJV, LazarusSC, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med, 2005; 352(15):1519-1528.
52.
ChauhanBF, ChartrandC, DucharmeFM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev, 2012;(12):CD009611.
ColeCH, ColtonT, ShahBL, AbbasiS, MacKinnonBL, DemissieS, FrantzID. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med, 1999; 340(13):1005-1010.
55.
AdcockIM, GilbeyT, GelderCM, ChungKF, BarnesPJ. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med, 1996; 154(3):771-782.
56.
LeachC, ColiceGL, LuskinA. Particle size of inhaled corticosteroids: does it matter?. J Allergy Clin Immunol, 2009; 124(6 Suppl):S88-S93.
57.
GrossG, ThompsonPJ, ChervinskyP, Vanden BurgtJ. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate 800 μg, for the treatment of moderate asthma. Chest, 1999; 115(2):343-351.
58.
DaviesRJ, StamponeP, O'ConnorBJ. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med, 1998; 92(Suppl A):23-31.
59.
CorrenJ, NelsonH, GreosLS, BenschG, GoldsteinM, WuJ, et al. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allery Asthma Immunol, 2001; 87(5):405-411.
60.
AmiravI, NewhouseMT, MinocchieriS, Castro-RodriguezJA, SchüeppKG. Factors that affect the efficacy of inhaled corticosteroids for infants and young children. J Allergy Clin Immunol, 2010; 125(6):1206-1211.
61.
HirstC, CalingaertB, StanfordR, CastellsagueJ. Use of long-acting beta-agonists and inhaled steroids in asthma: a meta-analysis of observational studies. J Asthma, 2010; 47(4):439-446.
CazzolaM, PageC, MateraMG. Long-acting muscarinic receptor antagonists for treatment of respiratory disease. Pulm Pharmacol Ther, 2013; 26(3):307-317.
64.
PetersSP, KunselmanSJ, IcitovicN, MooreWC, PascualR, AmeredesBT, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med, 2010; 363(18):1715-1726.
65.
KerstjensHA, EngelM, DahlR, PaggiaroP, BeckE, VandewalkerM, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med, 2012; 367(13):1198-1207.
66.
FuhrR, MagnussenH, SaremK, LloveraAR, KirstenAM, FalquésM, et al. Efficacy of aclidinium bromide 400 μgram twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest, 2012; 141(3):745-752.
67.
SinghS, LokeYK, EnrightPL, FurbergCD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systemic review and meta-analysis of randomized controlled trials. BMJ, 2011; 342:d3215.
68.
WiseRA, AnzuetoA, CottonD, DahlR, DevinsT, DisseB, et al. Tiotropium Respimat Inhaler and the risk of death in COPD. N Engl J Med, 2013; 369(16):1491-1501.
69.
TashkinDP, FergusonGT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res, 2013; 14(1):49.
70.
PowellCV. The role of magnesium sulfate in acute asthma: does route of administration make a difference?. Curr Opin Pulm Med, 2014; 20(1):103-108.
71.
HughesR, GoldkornA, MasoliM, WeatherallM, BurgessC, BeasleyR. Use of isotonic nebulized magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomized placebo-controlled trial. Lancet, 2003; 361(9375):2114-2117.
72.
GoodacreS, CohenJ, BradburnM, StevensJ, GrayA, BengerJ, CoatsT. The 3Mg trial: a randomized controlled trial of intravenous or nebulized magnesium sulphate versus placebo in adults with acute severe asthma. Health Technol Assess, 2014; 18(22):1-168.
73.
PowellC, Kolamunnage-DonaR, LoweJ, BolandA, PetrouS, DoullI, et al. Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomized placebo-controlled trial. Lacet Respir Med, 2013; 1(4):301-308.
74.
MahajanP, HaritosD, RosenbergN, ThomasR. Comparison of nebulized magnesium sulfate plus albuterol to nebulized albuterol plus saline in children with acute exacerbations of mild to moderate asthma. J Emerg Med, 2004; 27(1):21-25.
75.
StormsW, KalinerMA. Cromolyn sodium: fitting an old friend into current asthma treatment. J Asthma, 2005; 42(2):79-89.
76.
Van der WoudenJC, UijenJH, BernsenRM, TascheMJ, de JongsteJC, DucharmeFM. Inhaled sodium cromoglycate for asthma in children. Cochrane Database Syst Rev, 2008;(4):CD002173.
77.
KellerM, Schierholz. Have inadequate delivery systems hampered the clinical success of inhaled disodium cromoglycate? Time for reconsideration. Expert Opin Drug Deliv, 2011; 8(1):1-17.
78.
OhnishiT, KitaH, MayenoAN, OkadaS, SurS, BroideDH, GleichGJ. Lidocaine in bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil-active cytokines. Clin Exp Immunol, 1996; 104(2):325-331.
79.
OkadaS, HaganJB, KatoM, Bankers-FulbrightJL, HuntLW, GleichGJ, KitaH. Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils. J Immunol, 1998; 160(8):4010-4017.
80.
HuntLW, FrigasE, ButterfieldJH, KitaH, BlomgrenJ, DunnetteSL, et al. Treatment of asthma with nebulized lidocaine: a randomized, placebo-controlled trial. J Allergy Clin Immunol, 2004; 113(5):853-859.
81.
AbuanT, YeagerM, MontgomeryAB. Inhaled lidocaine for the treatment of asthma: lack of efficacy in two double-blind, randomized, placebo-controlled clinical studies. J Aerosol Med Pulm Drug Deliv, 2010; 23(6):381-388.
82.
MitrukaSN, WonA, McCurryKR, ZeeviA, McKaveneyT, VenkataramananR, et al. In the lung aerosol cyclosporine provides a regional concentration advantage over intramuscular cyclosporine. J Heart Lung Transplant, 2000; 19(10):969-975.
83.
DowlingRD, ZenatiM, BurckartGJ, YousemSA, SchaperM, SimmonsRL, et al. Aerosolized cyclosporine as single-agent immunotherapy in canine lung allografts. Surgery, 1990; 108(2):198-204.
84.
IaconoAT, CorcoranTE, GriffithBP, GrgurichWF, SmithDA, ZeeviA, et al. Aerosol cyclosporine therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J, 2004; 23(3):384-390.
85.
IaconoAT, KeenanRJ, DuncanSR, SmaldoneGC, DauberJH, ParadisIL, et al. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med, 1996; 153(4):1451-1455.
86.
IaconoAT, JohnsonBA, GrgurichWF, YoussefJG, CorcoranTE, SeilerDA, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med, 2006; 354(2):141-150.
87.
RohatagiS, CalicF, HardingN, OzouxML, BouriotJP, KirkesseliS, et al. Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporine A (ADI628) after single and repeated administration in health male and female subjects and asthmatic patients. J Clin Pharmacol, 2000; 40(11):1211-1226.
88.
AhmedT, GonzalezBJ, DantaI. Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin. Am J Respir Crit Care Med, 1999; 160(2):576-581.
89.
StelmachI, JerzynskaJ, StelmachW, MajakP, BrzozowskaA, GorskiP, KunaP. The effect of inhaled heparin on airway responsiveness to histamine and leukotriene D4. Allergy Asthma Proc, 2003; 24(1):59-65.
90.
WalkerPA, ShahSK, LetourneauPA, AllisonND, CoxCS. Treatment of plastic bronchitis using serial flexible bronchoscopy and aerosolized heparin therapy. Eur J Pediatr Surg, 2013; 23(2):157-160.
91.
MillerAC, ElaminEM, SuffrediniAF. Inhaled anticoagulation regimens for the treatment of smoke inhalation-associated acute lung injury: a systematic review. Crit Care Med, 2014; 42(2):413-419.
92.
DesaiMH, MlcakR, RichardsonJ, NicholsR, HerndonDN. Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/N-acetylcystine therapy. J Burn Care Rehabil, 1998; 19(3):210-212.
93.
MillerAC, RiveroA, ZiadS, SmithDJ, ElaminEM. Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res, 2009; 30(2):249-256.
94.
RiveroA, ElaminE, NguyenV, CruseW, SmithD. Can nebulized heparin and N-acetylcysteine reduce acute lung injury after inhalation lung insult?. Chest, 2007; 132(4):565.
95.
KanohS, TanabeT, RubinBK. Dapsone inhibits IL-8 secretion from human bronchial epithelial cells stimulated with lipopolysaccharide and resolves airway inflammation in the ferret. Chest, 2011; 140(4):980-990.
96.
NuhoğluC, Yaşar KiliçM, CeranO. Effectiveness of inhaled furosemide added to nebulized salbutamol in children with acute asthma. Allergol Immunopathol, 2006; 34(2):54-58.
97.
StiglianiM, AquinoRP, Del GaudioP, MencheriniT, SansoneF, RussoP. Non-steroidal anti-inflammatory drug for pulmonary administration: design and investigation of ketoprofen lysinate fine dry powder. Int J Pharm, 2013; 448(1):198-204.
98.
BusseWW, MiddletonE, StormsW, DockhornRJ, ChuTJ, GrossmanJ, et al. Corticosteroid-sparing effect of azelastine in the management of bronchial asthma. Am J Respir Crit Care Med, 1996; 153(1):122-127.
99.
LauterbachR, Szymura-OleksiakJ, PawlikD, WarchołJ, Lisowska-MiszczykI, RytlewskiK. Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: a pilot clinical study. J Matern Fetal Neonatal Med, 2006; 19(7):433-438.
100.
DiazKT, SkariaS, HarrisK, SolomitaM, LauS, BauerK, et al. Delivery and safety of inhaled interferon-γ in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv, 2012; 25(2):79-87.
101.
WaxPM, BeckerCE, CurrySC. Unexpected “gas” casualties in Moscow: a medical toxicology perspective. Ann Emerg Med, 2003; 41(5):700-705.
102.
DershwitzM, WalshJL, MorishigeRJ, ConnorsPM, RubsamenRM, ShaferSL, RosowCE. Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. Anesthesiology, 2000; 93(3):619-628.
103.
KrajnikM, PodolecZ, SiekierkaM, SykuteraM, PufalE, SobanskiP, et al. Morphine inhalation by cancer patients: a comparison of different nebulization techniques using pharmacokinetic, spirometric, and gasometric parameters. J Pain Symptom Manage, 2009; 38(5):747-757.
104.
MacLeodDB, HabibAS, IkedaK, SpykerDA, CassellaJV, HoKY, GanTJ. Inhaled fentanyl aerosol in healthy volunteers: pharmacokinetics and pharmacodynamics. Anesth Analg, 2012; 115(5):1071-1077.
105.
MasoodAR, ThomasSH. Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects. Br J Clin Pharmacol, 1996; 41(3):250-252.
106.
XuX, WangX, GeW, PanL, ZhengM. The pharmacokinetics of inhaled morphine delivered by an ultrasonic nebulizer in ventilated dogs. J Aerosol Med Pulm Drug Deliv, 2012; 25(1):41-46.
107.
ThipphawongJB, BabulN, MorishigeRJ, FindlayHK, ReberKR, MillwardGJ, OtulanaBA. Analgesic efficacy of inhaled morphine in patients after bunionectomy surgery. Anesthesiology, 2003; 99(3):693-700.
108.
MinerJR, KlettiC, HeroldM, HubbardD, BirosMH. Randomized clinical trial of nebulized fentanyl citrate versus IV fentanyl citrate in children presenting to the emergency department with acute pain. Acad Emerg Med, 2007; 14(10):895-898.
109.
FuldaGJ, GibersonF, FagraeusL. A prospective randomized trial of nebulized morphine compared with patient-controlled analgesia morphine in the management of acute thoracic pain. J Trauma, 2005; 59(2):383-388; discussion 389-390.
110.
BallasSK, ViscusiER, EpsteinKR. Management of acute chest wall sickle cell pain with nebulized morphine. Am J Hematol, 2004; 76(2):190-191.
111.
BounesV, DucasséJL, BonaAM, BattefortF, Houze-CerfonCH, LauqueD. Nebulized morphine for analgesia in an emergency setting. J Opioid Manag, 2009; 5(1):23-26.
112.
ZebraskiSE, KochenashSM, RaffaRB. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci, 2000; 66(23):2221-2231.
113.
JenningsAL, DaviesAN, HigginsJP, BroadleyK. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database System Rev, 2001;(4)CD002066.
114.
NosedaA, CarpiauxJP, MarksteinC, MeyvaertA, de MaertelaerV. Disabling dyspnea in patients with advanced disease: lack of effect of nebulized morphine. Eur Respir J, 1997; 10(5):1079-1083.
115.
JankelsonD, HosseiniK, MatherLE, SealeJP, YoungIH. Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. Eur Respir J, 1997; 10(10):2270-2274.
116.
CharlesMA, ReymondL, IsraelF. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage, 2008; 36(1):29-38.
117.
CullenL, TaylorD, TaylorS, ChuK. Nebulized lidocaine decreases the discomfort of nasogastric tube insertion: a randomized, double-blind trial. Ann Emerg Med, 2004; 44(2):131-137.
118.
GrahamDR, HayJG, ClagueJ, NisarM, EarisJE. Comparison of three different methods used to achieve local anesthesia for fiberoptic bronchoscopy. Chest, 1992; 102(3):704-707.
119.
GjonajST, LowenthalDB, DozorAJ. Nebulized lidocaine administered to infants and children undergoing flexible bronchoscopy. Chest, 1997; 112(6):1665-1669.
120.
KundraP, KutralamS, RavishankarM. Local anaesthesia for awake fibreoptic nasotracheal intubation. Acta Anaesthesiol Scand, 2000; 44(5):511-516.
121.
StolzD, ChhajedPN, LeuppiJ, PflimlinE, TammM. Nebulized lidocaine for flexible bronchoscopy: a randomized, double-blind, placebo-controlled trial. Chest, 2005; 128(3):1756-1760.
122.
BablFE, GoldfinchC, MandrawaC, CrellinD, O'SullivanR, DonathS. Does nebulized lidocaine reduce the pain and distress of nasogastric tube insertion in young children? A randomized, double-blind, placebo-controlled trial. Pediatrics, 2009; 123(6):1548-1555.
123.
GuayJ. Methemoglobinemia related to local anesthetics: a summary of 242 episodes. Anesth Analg, 2009; 108(3):837-845.
124.
MoustafaMA. Nebulized lidocaine alone or combined with fentanyl as a premedication to general anesthesia in spontaneously breathing pediatric patients undergoing rigid bronchoscopy. Paediatr Anaesth, 2013; 23(5):429-434.
125.
ShirkMB, DonahueKR, ShirvaniJ. Unlabeled uses of nebulized medications. Am J Health Syst Pharm, 2006; 63(18):1704-1716.
126.
LewisJF, TaborB, IkegamiM, JobeAH, JosephM, AbsolomD. Lung function and surfactant distribution in saline-lavaged sheep given instilled vs nebulized surfactant. J Appl Physiol, 1993; 74(3):1256-1264.
127.
CalverleyPM, AndersonJA, CelliB, FergusonGT, JenkinsC, JonesPW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007; 356(8):775-789.
128.
FinerNN, MerrittTA, BernsteinG, JobL, MazelaJ, SegalR. An open label, pilot study of Aerosurf combined with nCPAP to prevent RDS in preterm neonates. J Aerosol Med Pulm Drug Deliv, 2010; 23(5):303-309.
129.
KanmazHG, ErdeveO, CanpolatFE, MutluB, DilmenU. Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics, 2013; 131(2):e502-e509.
130.
Abdel-LatifME, OsbornDA. Pharyngeal instillation of surfactant before the first breath for prevention of morbidity and mortality in preterm infants at risk of respiratory distress syndrome. Cochrane Database Syst Rev, 2011; 16;(3):CD008311.
131.
DijkPH, HeikampA, Bambang OetomoS. Surfactant nebulization prevents the adverse effects of surfactant therapy on blood pressure and cerebral blood flow in rabbits with severe respiratory failure. Intensive Care Med, 1997; 23(10):1077-1081.
132.
StevensTP, HarringtonEW, BlennowM, SollRF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev, 2007;(4):CD003063.
133.
WillsonDF, TruwitJD, ConawayMR, TraulCS, EganEA. The Adult Calfactant in Acute Respiratory Distress Syndrome (CARDS) Trial. Chest, in press.
134.
GolshahiL, TianG, AzimiM, SonYJ, WalengaR, LongestPW, HindleM. The use of condensational growth methods for efficient drug delivery to the lungs during noninvasive ventilation high flow therapy. Pharm Res, 2013; 30(11):2917-2930.
135.
LongestPW, TianG. Development of a new technique for the efficient delivery of aerosolized medications to infants on mechanical ventilation. Pharm Res, 2015; 32(1):321-336.
